Back to Results
First PageMeta Content
Choroidal neovascularization / Ranibizumab / Macular degeneration / Vision / Maculopathy / Vascular endothelial growth factor / Myopia / Genentech / Macular edema / Ophthalmology / Medicine / Health


Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca
Add to Reading List

Document Date: 2015-05-13 10:22:10

Open Document

File Size: 209,53 KB

Share Result on Facebook

City

Toronto / Basel / Dorval / /

Company

Novartis Group / Novartis Pharmaceuticals Canada Inc. / Media Relations Julie Schneiderman Novartis Pharmaceuticals Canada Inc. / Genentech Inc. / AMD / Novartis Pharmaceuticals Inc. / /

Country

Switzerland / United States / Canada / /

Currency

USD / /

/

Event

FDA Phase / /

Facility

Michael’s Hospital / /

IndustryTerm

generic pharmaceuticals / healthcare field / over-the-counter and animal health products / healthcare solutions / /

MedicalCondition

myopia / pathologic myopia / macular edema / disease / macular degeneration / K et al. Myopic Choroidal Neovascularization / pathological myopia / choroidal neovascularization secondary / choroidal neovascularization / diabetic macular edema / retinal vein occlusion / infection / inflammation / myopic choroidal neovascularization / blindness / /

Organization

St. Michael’s Hospital in Toronto / Association for Research / /

Person

Harry Tiefenbach / Silva R. Myopic / David Wong / /

/

Position

leader / artist / physician / representative / /

Product

Visudyne / Lucentis / Canada / 1A9 / Lucentis® / Lucentis® (ranibizumab) / /

ProvinceOrState

Quebec / /

URL

http /

SocialTag